Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma

Area of Science:

• Oncology
• Genetics
• Immunology

Background:

• Metastasis mechanisms in pheochromocytoma/paraganglioma (mPPGL) remain largely unknown, limiting effective treatments for patients with metastatic disease.
• Current therapeutic strategies for mPPGL are hindered by a lack of understanding of the underlying molecular drivers of metastasis.

Purpose of the Study:

• To elucidate the genomic and transcriptomic landscape of mPPGL to identify prognostic markers and therapeutic targets.
• To characterize the tumor microenvironment and its relationship with genomic subtypes and clinical behavior in mPPGL.
• To explore the potential of immunotherapy by analyzing immune parameters in mPPGL.

Main Methods:

• Genomic profiling of a large mPPGL cohort, including mutational load, microsatellite instability, and copy-number alterations.
• Transcriptomic analysis to define signaling networks and establish a gene signature for mPPGL.
• Immunogenomic analysis and immunohistochemistry to assess the tumor microenvironment and immune cell infiltration.

Main Results:

• High mutational load, microsatellite instability, and copy-number alteration burden are associated with ATRX/TERT alterations and serve as prognostic markers in mPPGL.
• A mPPGL-specific gene signature was identified, highlighting CDK1 as a potential marker.
• A predominantly immunosuppressive tumor microenvironment was observed in mPPGL, with PD-L1 expressing MAML3-related tumors being an exception.

Conclusions:

• Genomic alterations like high mutational load and ATRX/TERT alterations are canonical markers for mPPGL metastasis risk.
• The study suggests incorporating immune parameters into clinical management for mPPGL prognostication.
• Identifying patients who may benefit from immunotherapy is a key implication of this research.